<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482260</url>
  </required_header>
  <id_info>
    <org_study_id>microRNA5</org_study_id>
    <nct_id>NCT01482260</nct_id>
  </id_info>
  <brief_title>Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma</brief_title>
  <official_title>Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous
      malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression
      profiling using microarrays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous
      malignant melanoma (CMM). With regards to a rapidly growing number of newly discovered miRNA
      sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous
      malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign
      melanocytic naevi (BMN) is limited. Patients with PCMM, CMMM and BMN are included in the
      study to perform an exploratory analysis by miRNA expression profiling using microarrays.
      Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative
      polymerase chain reaction (RT-PCR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Cutaneous Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Primary Cutaneous Malignant Melanoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous Malignant Melanoma Metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign Melanocytic Nevi</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Biopsy</description>
    <arm_group_label>Primary Cutaneous Malignant Melanoma</arm_group_label>
    <arm_group_label>Cutaneous Malignant Melanoma Metastases</arm_group_label>
    <arm_group_label>Benign Melanocytic Nevi</arm_group_label>
    <other_name>n.a.</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      skin biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with

          -  Primary Cutaneous Malignant Melanoma

          -  Cutaneous Malignant Melanoma Metastases

          -  Benign Melanocytic Naevi
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary Cutaneous Malignant Melanoma

          -  Cutaneous Malignant Melanoma Metastases

          -  Benign Melanocytic Naevi

        Exclusion Criteria:

        - Other Skin Cancer than Primary Cutaneous Malignant Melanoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Falk G Bechara, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Altmeyer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, Altmeyer P, Bechara FG. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013 Jan;351(1):85-98. doi: 10.1007/s00441-012-1514-5. Epub 2012 Oct 31.</citation>
    <PMID>23111773</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Michael Sand</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

